251 related articles for article (PubMed ID: 28176893)
1. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
Wedzicha JA; Zhong N; Ichinose M; Humphries M; Fogel R; Thach C; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2017; 12():339-349. PubMed ID: 28176893
[TBL] [Abstract][Full Text] [Related]
2. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Vogelmeier C; Zhong N; Humphries MJ; Mezzi K; Fogel R; Bader G; Patalano F; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():3189-3197. PubMed ID: 28008244
[TBL] [Abstract][Full Text] [Related]
3. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Anzueto AR; Vogelmeier CF; Kostikas K; Mezzi K; Fucile S; Bader G; Shen S; Banerji D; Fogel R
Int J Chron Obstruct Pulmon Dis; 2017; 12():1325-1337. PubMed ID: 28496316
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
[TBL] [Abstract][Full Text] [Related]
5. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
[TBL] [Abstract][Full Text] [Related]
8. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Anzueto AR; Kostikas K; Mezzi K; Shen S; Larbig M; Patalano F; Fogel R; Banerji D; Wedzicha JA
Respir Res; 2018 Jun; 19(1):121. PubMed ID: 29925383
[TBL] [Abstract][Full Text] [Related]
9. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
Greulich T; Kostikas K; Gaga M; Aalamian-Mattheis M; Lossi NS; Patalano F; Nunez X; Pagano VA; Fogel R; Vogelmeier CF; Clemens A
Int J Chron Obstruct Pulmon Dis; 2018; 13():1229-1237. PubMed ID: 29713156
[TBL] [Abstract][Full Text] [Related]
10. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
Kardos P; Hagedorn-Peinz I
Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Rhee CK; Park HY; Park JW; Lee JH; Kim TH; Lee SW; Jung JY; Kim S; Hwang YI; Jung KS
Trials; 2017 Feb; 18(1):80. PubMed ID: 28228162
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
[TBL] [Abstract][Full Text] [Related]
15. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA; Banerji D; Chapman KR; Vestbo J; Roche N; Ayers RT; Thach C; Fogel R; Patalano F; Vogelmeier CF;
N Engl J Med; 2016 Jun; 374(23):2222-34. PubMed ID: 27181606
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
[TBL] [Abstract][Full Text] [Related]
18. [Study of the month : FLAME study in chronic obstructive pulmonary disease].
Corhay JL
Rev Med Liege; 2016 Sep; 71(9):400-406. PubMed ID: 28383836
[TBL] [Abstract][Full Text] [Related]
19. Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Ficker JH; Rabe KF; Welte T
Pulm Pharmacol Ther; 2017 Aug; 45():19-33. PubMed ID: 28389258
[TBL] [Abstract][Full Text] [Related]
20. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N; Kaneko T
Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
